Thymmune Therapeutics

About Thymmune Therapeutics

Thymmune Therapeutics is a biotechnology company focused on developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. Their cutting-edge approach in iPSC-thymic cell manufacturing enables the generation of off-the-shelf cells at scale, with a pipeline of therapies targeting immunodeficiencies, transplant-related issues, and autoimmune disorders.

Products & Services

Thymic Cell Engineering Platform:A machine learning-enabled platform for mass production of iPSC-derived thymic cells to restore immune function through a scalable, less invasive approach.

Therapies for Immune Disorders:A pipeline of therapies to treat immunodeficiencies, transplant-related conditions, and autoimmune disorders.

Specialties

Thymic Cell Engineering Machine Learning in Biotechnology iPSC-derived Cell Manufacturing Immunology Therapies for Immune Disorders Healthier Aging Solutions

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 37000000 MR: - FA: 37 million FAN: 37000000	D: 2023-09-29 FD: 2023-09-29	1 investors
2	RT: Seed T: - FT: Seed	A: 7000000 MR: - FA: $7 million FAN: 7000000	D: 2023-03-01 FD: 2023-03-01	8 investors

Grant Latest

2023-09-29

$37.0M

1 investor (Pro only)

Seed 2023-03-01

$7.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Stan Wang

CEO & Founder

LinkedIn (Pro only)

B

Bing Lim

CHIEF SCIENTIFIC OFFICER

LinkedIn (Pro only)

M

Manish Jain

CTO

LinkedIn (Pro only)

J

Jacob Dion

R&D Intern

Q

Qiumei Du

Principal Scientist

B

Behzad Gerami-Naini

Principal Scientist

View 20 more team members with Pro

Unlock Full Team Directory

Recent News